An autologous cartilage tissue implant neocart for treatment of grade III chondral injury to the distal femur: Prospective clinical safety trial at 2 years

Dennis Crawford, Chelsea M. Heveran, W. Dilworth Cannon, Li Foong Foo, Hollis G. Potter

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Background: The healing potential of damaged articular cartilage is limited. The NeoCart is a tissue-engineered collagen matrix seeded with autogenous chondrocytes designed for the repair of hyaline articular cartilage. Hypothesis: The NeoCart implant is well tolerated in the human knee. Study Design: Case series; Level of evidence, 4. Methods: Eight patients (treatment group) with full-thickness cartilage injury were treated with the NeoCart and evaluated prospectively. Autogenous chondrocytes provided by arthroscopic biopsy were seeded into a 3-dimensional type I collagen scaffold. The seeded scaffold was subjected to a tissue-engineering protocol including treatment with a bioreactor. Implantation of the prepared cartilage tissue patch was performed via miniarthrotomy and secured with a collagen bioadhesive. Evaluations through 24 months postoperatively included the subjective International Knee Documentation Committee questionnaire, visual analog scale, range of motion, and cartilage-sensitive magnetic resonance imaging (MRI), including quantitative T2 mapping. Results: Pain scores after NeoCart implantation were significantly lower than baseline at 12 and 24 months after the procedure (P

Original languageEnglish (US)
Pages (from-to)1334-1343
Number of pages10
JournalAmerican Journal of Sports Medicine
Volume37
Issue number7
DOIs
StatePublished - 2009

Fingerprint

Femur
Cartilage
Clinical Trials
Articular Cartilage
Chondrocytes
Safety
Knee
Wounds and Injuries
Collagen
Hyaline Cartilage
Bioreactors
Tissue Engineering
Clinical Protocols
Articular Range of Motion
Collagen Type I
Visual Analog Scale
Documentation
Therapeutics
Magnetic Resonance Imaging
Biopsy

Keywords

  • Articular cartilage injury
  • Cartilage repair
  • Chondral repair
  • Chondrocyte

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Physical Therapy, Sports Therapy and Rehabilitation
  • Medicine(all)

Cite this

An autologous cartilage tissue implant neocart for treatment of grade III chondral injury to the distal femur : Prospective clinical safety trial at 2 years. / Crawford, Dennis; Heveran, Chelsea M.; Cannon, W. Dilworth; Foo, Li Foong; Potter, Hollis G.

In: American Journal of Sports Medicine, Vol. 37, No. 7, 2009, p. 1334-1343.

Research output: Contribution to journalArticle

@article{3d0feac398ed413faee9bf1aa5ddedde,
title = "An autologous cartilage tissue implant neocart for treatment of grade III chondral injury to the distal femur: Prospective clinical safety trial at 2 years",
abstract = "Background: The healing potential of damaged articular cartilage is limited. The NeoCart is a tissue-engineered collagen matrix seeded with autogenous chondrocytes designed for the repair of hyaline articular cartilage. Hypothesis: The NeoCart implant is well tolerated in the human knee. Study Design: Case series; Level of evidence, 4. Methods: Eight patients (treatment group) with full-thickness cartilage injury were treated with the NeoCart and evaluated prospectively. Autogenous chondrocytes provided by arthroscopic biopsy were seeded into a 3-dimensional type I collagen scaffold. The seeded scaffold was subjected to a tissue-engineering protocol including treatment with a bioreactor. Implantation of the prepared cartilage tissue patch was performed via miniarthrotomy and secured with a collagen bioadhesive. Evaluations through 24 months postoperatively included the subjective International Knee Documentation Committee questionnaire, visual analog scale, range of motion, and cartilage-sensitive magnetic resonance imaging (MRI), including quantitative T2 mapping. Results: Pain scores after NeoCart implantation were significantly lower than baseline at 12 and 24 months after the procedure (P",
keywords = "Articular cartilage injury, Cartilage repair, Chondral repair, Chondrocyte",
author = "Dennis Crawford and Heveran, {Chelsea M.} and Cannon, {W. Dilworth} and Foo, {Li Foong} and Potter, {Hollis G.}",
year = "2009",
doi = "10.1177/0363546509333011",
language = "English (US)",
volume = "37",
pages = "1334--1343",
journal = "American Journal of Sports Medicine",
issn = "0363-5465",
publisher = "SAGE Publications Inc.",
number = "7",

}

TY - JOUR

T1 - An autologous cartilage tissue implant neocart for treatment of grade III chondral injury to the distal femur

T2 - Prospective clinical safety trial at 2 years

AU - Crawford, Dennis

AU - Heveran, Chelsea M.

AU - Cannon, W. Dilworth

AU - Foo, Li Foong

AU - Potter, Hollis G.

PY - 2009

Y1 - 2009

N2 - Background: The healing potential of damaged articular cartilage is limited. The NeoCart is a tissue-engineered collagen matrix seeded with autogenous chondrocytes designed for the repair of hyaline articular cartilage. Hypothesis: The NeoCart implant is well tolerated in the human knee. Study Design: Case series; Level of evidence, 4. Methods: Eight patients (treatment group) with full-thickness cartilage injury were treated with the NeoCart and evaluated prospectively. Autogenous chondrocytes provided by arthroscopic biopsy were seeded into a 3-dimensional type I collagen scaffold. The seeded scaffold was subjected to a tissue-engineering protocol including treatment with a bioreactor. Implantation of the prepared cartilage tissue patch was performed via miniarthrotomy and secured with a collagen bioadhesive. Evaluations through 24 months postoperatively included the subjective International Knee Documentation Committee questionnaire, visual analog scale, range of motion, and cartilage-sensitive magnetic resonance imaging (MRI), including quantitative T2 mapping. Results: Pain scores after NeoCart implantation were significantly lower than baseline at 12 and 24 months after the procedure (P

AB - Background: The healing potential of damaged articular cartilage is limited. The NeoCart is a tissue-engineered collagen matrix seeded with autogenous chondrocytes designed for the repair of hyaline articular cartilage. Hypothesis: The NeoCart implant is well tolerated in the human knee. Study Design: Case series; Level of evidence, 4. Methods: Eight patients (treatment group) with full-thickness cartilage injury were treated with the NeoCart and evaluated prospectively. Autogenous chondrocytes provided by arthroscopic biopsy were seeded into a 3-dimensional type I collagen scaffold. The seeded scaffold was subjected to a tissue-engineering protocol including treatment with a bioreactor. Implantation of the prepared cartilage tissue patch was performed via miniarthrotomy and secured with a collagen bioadhesive. Evaluations through 24 months postoperatively included the subjective International Knee Documentation Committee questionnaire, visual analog scale, range of motion, and cartilage-sensitive magnetic resonance imaging (MRI), including quantitative T2 mapping. Results: Pain scores after NeoCart implantation were significantly lower than baseline at 12 and 24 months after the procedure (P

KW - Articular cartilage injury

KW - Cartilage repair

KW - Chondral repair

KW - Chondrocyte

UR - http://www.scopus.com/inward/record.url?scp=70350043831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350043831&partnerID=8YFLogxK

U2 - 10.1177/0363546509333011

DO - 10.1177/0363546509333011

M3 - Article

C2 - 19448048

AN - SCOPUS:70350043831

VL - 37

SP - 1334

EP - 1343

JO - American Journal of Sports Medicine

JF - American Journal of Sports Medicine

SN - 0363-5465

IS - 7

ER -